Legend Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,029	627.3	285.1	116.68	65.4
Other Revenue	-	-	-	0.33	3.42
Revenue	1,029	627.3	285.1	117.01	68.83
Revenue Growth (YoY)	64.02%	120.03%	143.66%	70.00%	-8.23%
Cost of Revenue	822.8	648.1	526.4	401.01	313.35
Gross Profit	206.1	-20.8	-241.3	-284.01	-244.52
Selling, General & Admin	341.6	284.3	201	174.05	149.5
Other Operating Expenses	1	-	85.8	-	-
Operating Expenses	342.6	284.3	286.8	174.05	149.5
Operating Income	-136.5	-305.1	-528.1	-458.05	-394.02
Interest Expense	-21.4	-21.6	-21.8	-10.8	-0.9
Interest & Investment Income	40.1	61.2	54.5	8.18	0.97
Currency Exchange Gain (Loss)	-168.8	109.3	-28.2	-9.88	-
Other Non Operating Income (Expenses)	4	2.5	3.4	24.22	-12.27
EBT Excluding Unusual Items	-282.6	-153.7	-520.2	-446.33	-406.22
Gain (Loss) on Sale of Investments	-	-	-	0.6	-
Gain (Loss) on Sale of Assets	-	-	-	-	-0.97
Asset Writedown	-	-4.4	-	-	-
Pretax Income	-282.6	-158.1	-520.2	-445.72	-407.2
Income Tax Expense	14.2	18.9	-1.9	0.63	-3.61
Net Income	-296.8	-177	-518.3	-446.35	-403.58
Net Income to Common	-296.8	-177	-518.3	-446.35	-403.58
Shares Outstanding (Basic)	184	183	176	159	141
Shares Outstanding (Diluted)	184	183	176	159	141
Shares Change (YoY)	0.80%	3.84%	10.71%	12.91%	19.21%
EPS (Basic)	-1.61	-0.97	-2.94	-2.81	-2.87
EPS (Diluted)	-1.62	-0.97	-2.94	-2.81	-2.87
Free Cash Flow	-128.8	-158.1	-413.4	-222.21	-240.66
Free Cash Flow Per Share	-0.70	-0.86	-2.35	-1.40	-1.71
Gross Margin	20.03%	-3.32%	-84.64%	-242.73%	-
Operating Margin	-13.27%	-48.64%	-185.23%	-391.48%	-572.49%
Profit Margin	-28.85%	-28.22%	-181.80%	-381.48%	-586.38%
Free Cash Flow Margin	-12.52%	-25.20%	-145.00%	-189.91%	-349.67%
EBITDA	-127.1	-294.4	-517.4	-445.41	-385.88
EBITDA Margin	-12.35%	-46.93%	-181.48%	-	-
D&A For EBITDA	9.4	10.7	10.7	12.65	8.14
EBIT	-136.5	-305.1	-528.1	-458.05	-394.02
EBIT Margin	-13.27%	-48.64%	-185.23%	-	-
Revenue as Reported	1,029	627.3	285.1	117.01	68.83

Updated Mar 10, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q